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Objectives: This post hoc analysis assessed the safety of pemetrexed and platinum in combination with pem
brolizumab, including time-to-onset and time-to-resolution of all-cause any-grade and grade ≥3 adverse events
(AEs) and renal AEs.
Materials and Methods: Patient-level data from KEYNOTE-189 were analyzed in the all-subjects-as-treated pop
ulation (pembrolizumab arm, n = 405; placebo arm, n = 202), and among patients who received ≥5 cycles of
pemetrexed (pemetrexed/pembrolizumab/platinum arm, n = 310; pemetrexed/placebo/platinum arm, n = 135).
All-cause AEs were selected based on ≥2 % incidence from previously reported KEYNOTE-189 data and included
neutropenia, febrile neutropenia, anemia, thrombocytopenia, asthenia, fatigue, dyspnea, diarrhea, nausea,
vomiting, pneumonitis, and renal events. Descriptive statistics summarized all-cause AEs. Medians and inter
quartile ranges were used to examine time-to-onset and time-to-resolution. The data cutoff was November 8,
2017.
Results: In both treatment arms, most non-hematologic (nausea, vomiting, diarrhea, and asthenia), and hema
tologic (febrile neutropenia, thrombocytopenia, and neutropenia) grade ≥3 AEs with ≥2 % incidence had a
median time-to-onset within the first 4 cycles, and a median time-to-resolution of within 2 weeks from onset. A
small number of AEs had longer median time-to-onset (pneumonitis and fatigue) and median time-to-resolution
(pneumonitis, fatigue, acute kidney injury, and anemia). Among patients who received ≥5 cycles of pemetrexed,
the incidence of any-grade renal toxicity in the pemetrexed/pembrolizumab/platinum arm was 2.3 % in Cycles
1− 4, 4.8 % in Cycles 5− 8, 2.6 % in Cycles 9− 12, and 2.5 % in Cycles ≥13; and, in the pemetrexed/placebo/
platinum arm, 0.7 % in Cycles 1− 4, 1.5 % in Cycles 5− 8, 1.3 % in Cycles 9− 12, and 2.0 % in Cycles ≥13.
Conclusion: Pemetrexed/pembrolizumab/platinum has manageable toxicity with longer duration of treatment.
While the incidence of renal toxicity was slightly higher in the pembrolizumab combination as compared to
pemetrexed, the incidence did not increase in later treatment cycles. These results support the safe use of the
KEYNOTE-189 regimen in clinical practice.
Clinical Trial Registration Number: NCT02578680 (clinicaltrials.gov).

Abbreviations: PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand-1.
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1. Introduction

(including CONSORT flow diagram) [14]. Briefly, patients in this
double-blind, phase 3 study had pathological confirmed metastatic NSQ
NSCLC, without sensitizing EGFR or ALK mutations, and received no
prior systemic therapy for metastatic disease. Patients were randomly
assigned (2:1) to receive either 200 mg pembrolizumab or placebo. All
patients received pembrolizumab or placebo plus pemetrexed (500 mg
per square meter), administered intravenously every 3 weeks, in com
bination with 4 cycles of cisplatin (75 mg per square meter of body
surface area) or carboplatin (area under the concentration time curve,
5 mg per milliliter per minute). Treatment continued until radiographic
progression, unacceptable toxicity, investigator decision, patient with
drawal, or up to 35 cycles for pembrolizumab. If toxicity was clearly
attributed to 1 agent, that agent alone could be discontinued. Data re
ported here are from the interim analysis cutoff of November 8, 2017
(median follow-up time of 10.5 months).
The trial protocol and all amendments were approved by the
appropriate ethics panel at each center. The trial was conducted in
accordance with the Declaration of Helsinki and was overseen by an
external monitoring committee. All patients provided informed written
consent prior to enrollment.

The approvals of several immune checkpoint inhibitors have
advanced the standard-of-care for patients with metastatic non-small
cell lung cancer (NSCLC) in first-line settings and after platinum-based
chemotherapy treatment failure [1–3]. The ability of immune check
point inhibitors to restore tumor-specific T cell responses has resulted in
substantial improvement of survival outcomes [4,5].
Preclinical and clinical studies suggest that combining immune
checkpoint inhibitors with chemotherapy improves immunotherapy
anti-tumor effects via various mechanisms, including reduced tumor
load, release of tumor antigens in vivo, and enhanced anti-tumor im
mune response [6]. Pemetrexed, an established, multi-targeted anti
folate, has demonstrated positive immune modulation [7]. In several
clinical trials of patients with advanced NSCLC, pemetrexed/platinum
demonstrated improvements in efficacy over standard-of-care, with a
tolerable safety profile in first-line and maintenance settings [8–10].
In 2017, the combination of pemetrexed/pembrolizumab/carbopla
tin was approved by the United States Food and Drug Administration as
a first-line treatment for metastatic nonsquamous (NSQ) NSCLC after
demonstrating a significantly improved overall response rate compared
with pemetrexed/carboplatin in the phase 2 KEYNOTE-021 study [11,
12]. The superior efficacy of pemetrexed/pembrolizumab/carboplatin
was subsequently confirmed in the phase 3 KEYNOTE-189 study [13,
14]. After a median follow-up of 10.5 months, pemetrexed/pem
brolizumab/platinum improved overall survival (OS; hazard ratio, 0.49,
p < 0.001) and progression-free survival (PFS; hazard ratio, 0.52,
p < 0.001) irrespective of PD-L1 expression, compared with pemetrex
ed/placebo/platinum [14]. Efficacy benefits were consistently demon
strated after a median follow-up of 23.1 months [13] and 31.0 months
[15].
The combination of pemetrexed/pembrolizumab/platinum has also
demonstrated a tolerable safety profile [13–15]. The proportion of pa
tients who experienced grade ≥3 adverse events (AEs) was similar
among those receiving pemetrexed/pembrolizumab/ platinum
compared with pemetrexed/placebo/platinum (71.9 % vs 66.8 %) [13].
The most common immune-mediated any-grade and grade ≥3 AEs
among patients receiving pemetrexed/pembrolizumab/platinum were
hypothyroidism (7.9 %) and pneumonitis (3.0 %), respectively [13]. A
greater percentage of those treated with pemetrexed/pem
brolizumab/platinum experienced acute kidney injury compared with
patients receiving pemetrexed/placebo/platinum (6.2 % vs 0.5 %) [13].
Real-world data from Flatiron Health’s database (May 2017 –
October 2019) show that, among patients continuing treatment after 4
cycles with pemetrexed/pembrolizumab/platinum, 37 % received
combination pembrolizumab and pemetrexed maintenance, while 41 %
received pembrolizumab monotherapy maintenance, and 21 % switched
between pemetrexed or pembrolizumab monotherapy and pem
brolizumab/pemetrexed combination maintenance therapy [16]. We
hypothesize this may be due to perceived toxicity concerns for the
maintenance combination of pembrolizumab/pemetrexed, particularly
renal toxicity [17]. However, to our knowledge, no study has examined
the safety profile of pembrolizumab/pemetrexed specifically in the
maintenance phase (Cycle 5 and beyond).
This study provides an in-depth assessment of the safety profile,
including renal toxicity, of pembrolizumab/pemetrexed over time in all
treated patients, and among patients who received pembrolizumab/
pemetrexed for ≥5 treatment cycles. The incidence of all-cause anygrade AEs and grade ≥3 AEs, as well as time-to-onset and time-toresolution of AEs, by study arm were also examined.

2.2. Patients
A total of 616 patients were allocated to either the pemetrexed/
pembrolizumab/platinum (n = 410) or pemetrexed/placebo/platinum
arm (n = 206) [13]. This analysis included 405 (98.9 %) patients from
the pemetrexed/pembrolizumab/platinum arm and 202 (98.1 %) from
the pemetrexed/placebo/platinum arm who received treatment (all-
subjects-as-treated population).
A subcohort of 310 (76.5 %) patients from the pemetrexed/pem
brolizumab/ platinum arm and 135 (66.8 %) patients from the peme
trexed/placebo/platinum arm who received ≥5 cycles of pemetrexed
were included in analyses investigating maintenance pemetrexed
therapy.
2.3. Outcomes
Adverse events of any cause were identified by system organ class
and preferred term (Medical Dictionary for Regulatory Activities
[MedDRA] 20.1). All-cause AEs of any-grade, as well as grade ≥3 AEs,
were investigated. The grade ≥3 AEs were identified based on previ
ously reported KEYNOTE-189 safety profiles and included grade ≥3 AEs
of any cause that occurred in ≥2 % of either treatment arm (specifically:
neutropenia, febrile neutropenia, anemia, thrombocytopenia, asthenia,
fatigue, dyspnea, diarrhea, nausea, vomiting, and pneumonitis) [13,14].
Renal adverse events were selected as a composite AE of special interest
and additionally investigated, as noted in previous KEYNOTE-189 re
sults [13,14]. Renal AEs were identified by system organ class and
preferred term (MedDRA 20.1). The composite term for renal events
included: acute kidney injury, chronic kidney disease, renal failure,
proteinuria, renal tubular necrosis, creatinine renal clearance decreased,
creatinine renal clearance increased, renal impairment, prerenal failure,
renal disorder, acute prerenal failure, renal infarct, and nephropathy.
Renal events and changes in serum creatinine were summarized every 4
cycles.
2.4. Statistical analyses
Descriptive statistics were used to summarize baseline demographic
and patient characteristics, as well as any-grade all-cause AEs, grade ≥3
all-cause AEs, renal AEs, and discontinuation due to AEs. Patient-level
median and interquartile ranges (IQR) for time-to-onset and time-toresolution of AEs were described. Patient-level data were analyzed for
the all-subjects-as-treated population, and separately for patients who
received pemetrexed for ≥5 cycles (maintenance population).

2. Materials and methods
2.1. Study design and treatment
The KEYNOTE-189 study design has been previously reported
54
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3.2.2. All-cause adverse events
All-cause any-grade AEs were reported in 404 (99.8 %) patients in
the pemetrexed/pembrolizumab/platinum arm, and 200 (99.0 %) pa
tients in the pemetrexed/placebo/platinum arm; all-cause grade ≥3 AEs
were reported in 272 (67.2 %) and 133 (65.8 %) patients in the peme
trexed/pembrolizumab/platinum arm and the pemetrexed/placebo/
platinum arm, respectively (Supplemental Table 2). The incidence of
grade ≥3 AEs was similar between the pemetrexed/pembrolizumab/
platinum and pemetrexed/placebo/platinum arms for both hematologic
and non-hematologic events for the all-subjects-as-treated population. A
breakdown of these AEs is included in Supplemental Table 2, and has
been previously described [14].
Of the grade ≥3 non-hematologic AEs, acute kidney injury, nausea,
vomiting, diarrhea, and asthenia all had a median time-to-onset within
the first 4 cycles of treatment for both study arms (Fig. 1, Panel A). In the
pemetrexed/pembrolizumab/platinum arm, pneumonitis was the only
grade ≥3 non-hematologic AE with a median time-to-onset that
occurred after the first 4 cycles and had a median time-to-onset of 125
days (6 cycles). In the pemetrexed/placebo/platinum arm, fatigue was
the only grade ≥3 non-hematologic AE with a median time-to-onset
occurring after the first 4 cycles (91 days; 4.3 cycles). The median
time-to-onset was the earliest (6 days) for grade ≥3 nausea, and the
latest for grade ≥3 pneumonitis, both in the pemetrexed/ pem
brolizumab/platinum arm (Fig. 1, Panel A). Grade ≥3 AEs of nausea,
vomiting, diarrhea, and asthenia all had a median time-to-resolution of
≤2 weeks from onset in both study arms (Fig. 1, Panel B). In the
pemetrexed/pembrolizumab/platinum arm, grade ≥3 pneumonitis and
grade ≥3 acute kidney injury had a median time-to-resolution of 25 days

3. Results
3.1. Baseline characteristics
Demographic and clinical characteristics of the all-subjects-astreated and the maintenance patient populations were similar in both
populations and were generally balanced between the pemetrexed/
pembrolizumab/platinum and pemetrexed/placebo/platinum arms
(Supplemental Table 1).
3.2. All-subjects-as-treated
3.2.1. Exposure to study treatment
Patients in the pemetrexed/pembrolizumab/platinum arm had a
mean treatment duration of 7.4 months (standard deviation [SD], 4.7);
334 (82.5 %) patients received 4 cycles of platinum, 320 (79.0 %)
received ≥5 cycles of pembrolizumab or pemetrexed, and only 9 (2.2 %)
entered the maintenance therapy phase without pemetrexed. In the
pemetrexed/placebo/platinum arm, the mean treatment duration was
5.4 months (SD, 4.3); 150 (74.3 %) patients received 4 cycles of plat
inum, 138 (68.3 %) patients received ≥5 cycles of pemetrexed or pla
cebo, and only 3 (1.5 %) patients entered the maintenance therapy
phase without pemetrexed. There were 113 (27.9 %) patients in the
pemetrexed/pembrolizumab/platinum arm who received ≥15 cycles of
any study drug; 86 (76.1 %) of these patients received ≥15 cycles of
pemetrexed. There were 30 (14.9 %) patients in the pemetrexed/pla
cebo/platinum arm who received ≥15 cycles of any study drug; 25 (83.3
%) of these patients received ≥15 cycles of pemetrexed.

Fig. 1. Time-to-onset (Panel A) and time-to-resolution (Panel B) of non-hematologic grade ≥3 adverse events that occurred in ≥2 % of the all-subjects-as treated
population. Abbreviations: IQR, interquartile range; N/A, not applicable; Pem, pemetrexed; Pembro, pembrolizumab; Plat, platinum, Q1, quartile 1; Q3, quartile 3.
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(3.6 weeks) and 24 days (3.4 weeks), respectively (Fig. 1, Panel B). In
the pemetrexed/pembrolizumab/platinum arm, grade ≥3 fatigue had a
median time-to-resolution within 2 weeks (11 days). In the pemetrexed/
placebo/platinum arm, grade ≥3 pneumonitis and grade ≥3 fatigue had
a median time-to-resolution of 19 days (2.7 weeks) and 128 days (18.3
weeks), respectively (Fig. 1, Panel B).
All hematologic grade ≥3 AEs (febrile neutropenia, thrombocyto
penia, neutropenia, and anemia) had a median time-to-onset within the
first 4 cycles (Fig. 2, Panel A). Most grade ≥3 hematologic AEs (febrile
neutropenia, thrombocytopenia, and neutropenia) had a median timeto-resolution within 2 weeks from onset (Fig. 2, Panel B). Grade ≥3
anemia had a median time-to-resolution of 21 days (3 weeks), and 11
days (1.6 weeks) in the pemetrexed/placebo/platinum arm and the
pemetrexed/pembrolizumab/platinum arm, respectively (Fig. 2, Panel
B).
Across all study cycles cumulatively, in the pemetrexed/pem
brolizumab/platinum arm, pemetrexed or pembrolizumab were dis
continued for 112 (27.7 %) patients due to AEs and, of these, 37 (33.0 %)
discontinued during the first 4 cycles. The discontinuation rate for
pemetrexed and pembrolizumab was similar across all treatment cycles,
never exceeding 3 % in any study cycle (Fig. 3).

median of 9.0 cycles (range, 5–24) of pemetrexed in the pemetrexed/
placebo/platinum arm.
3.3.2. All-cause adverse events
The proportion of grade ≥3 AEs is shown in both Fig. 4 (for indi
vidual AEs, by treatment arm), and Supplemental Fig. 1 (AEs with ≥2 %
incidence, by cycle). The incidence of grade ≥3 AEs increased moder
ately (by approximately 6–8 %) among patients in the pemetrexed/
pembrolizumab/platinum arm compared with the pemetrexed/pla
cebo/platinum arm in Cycles 9− 12 and ≥13 (Supplemental Fig. 1).
Grade ≥3 hematologic toxicities of neutropenia, thrombocytopenia, and
anemia occurred more frequently in the first 4 cycles compared with
Cycle 5 and later in both treatment arms (Fig. 4). Compared to patients
in the pemetrexed/placebo/platinum arm, patients in the pemetrexed/
pembrolizumab/platinum arm had a higher proportion of renal AEs
across all cycles (Fig. 4).
3.3.3. Immune-mediated adverse events
The two most common immune-mediated AEs were any-grade hy
pothyroidism, occurring in 25 (8.1 %) patients, and any-grade pneu
monitis, occurring in 15 (4.8 %) patients in the pemetrexed/
pembrolizumab/platinum arm. In the pemetrexed/placebo/platinum
arm, any-grade hypothyroidism occurred in 4 (3.0 %) patients, and anygrade pneumonitis in 3 (2.2 %) patients. Grade ≥3 hypothyroidism
occurred in 2 (0.6 %) patients in the pemetrexed/pembrolizumab/
platinum arm, and no patients in the pemetrexed/placebo/platinum
arm. Grade ≥3 pneumonitis occurred in 8 (2.6 %) patients in the

3.3. Patients receiving ≥5 cycles of pemetrexed (maintenance population)
3.3.1. Exposure to study treatment
In the pemetrexed/pembrolizumab/platinum arm, patients received
a median of 11 cycles (range, 5–30) of pemetrexed compared with a

Fig. 2. Time-to-onset (Panel A) and time-to-resolution (Panel B) of hematologic grade ≥3 adverse events that occurred in ≥2 % of the all-subjects-as treated
population.
Abbreviations: IQR, interquartile range; Pem, pemetrexed; Pembro, pembrolizumab; Plat, platinum; Q1, quartile 1; Q3, quartile 3.
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Fig. 3. The percentage of patients who discontinued either pemetrexed or pembrolizumab due to an adverse event in each cycle of treatment in pemetrexed/
pembrolizumab/platinum arm of the all-subjects-as-treated population.
Fig. 4. Incidence of grade ≥3 adverse events over cycles of
pemetrexed in patients who received ≥5 cycles of pemetrexed,
by study arm.
Data are a percentage of patients who experienced ≥1 grade ≥3
adverse event. The composite term for renal events included the
following Medical Dictionary for Regulatory Activities 20.1
preferred terms: acute kidney injury, chronic kidney disease,
renal failure, proteinuria, renal tubular necrosis, creatinine
renal clearance decreased, creatinine renal clearance increased,
renal impairment, prerenal failure, renal disorder, acute pre
renal failure, renal infarct, and nephropathy.

Table 1
Incidence of any-gradea renal adverse event over cycles of pemetrexed in patients who received ≥5 cycles of pemetrexed.
Pem/pembro/plat

nb (%)

Pem/placebo/plat

n = 310

Renal events
Acute kidney injury
Chronic kidney disease
Creatinine renal
clearance decreased
Renal failure
Other renal eventsc

n = 135

Cycles 1− 4
(n = 310)

Cycles 5− 8
(n = 310)

Cycles 9− 12
(n = 235)

Cycles ≥13
(n = 157)

Cycles 1− 4
(n = 135)

Cycles 5− 8
(n = 135)

Cycles 9− 12
(n = 78)

Cycles ≥13
(n = 51)

7 (2.3)
4 (1.3)
0
0

15 (4.8)
4 (1.3)
2 (0.6)
1 (0.3)

6 (2.6)
3 (1.3)
0
0

4 (2.5)
1 (0.6)
0
1 (0.6)

1 (0.7)
0
0
1 (0.7)

2 (1.5)
0
0
0

1 (1.3)
0
0
0

1 (2.0)
0
1 (2.0)
0

1 (0.3)
2 (0.6)

6 (1.9)
2 (0.6)

1 (0.4)
1 (0.4)

1 (0.6)
1 (0.6)

0
0

2 (1.5)
0

1 (1.3)
0

0
0

a

For the pemetrexed/pembrolizumab/platinum arm: in Cycles 1− 4, no grade ≥3 adverse events occurred; in Cycles 5− 8, n = 5 (1.6 %) grade ≥3 adverse events
occurred including 2 acute kidney injury (0.6 %), 1 acute prerenal failure (0.3 %), and 2 renal failure (0.6 %); in Cycles 9− 12, n = 1 (0.4 %) grade ≥3 adverse event
occurred (proteinuria); and in Cycles ≥13, n = 1 (0.4 %) grade ≥3 adverse event (acute kidney injury) occurred. In the pemetrexed/placebo/platinum arm, no grade
≥3 adverse events occurred in any of the study cycles. b The n reported in each column represents the patients who experienced ≥1 any-grade renal adverse event.
Percentages for each column were calculated based on column-specific sample sizes. c Other renal events include: acute prerenal failure, nephropathy, proteinuria,
renal disorder, and renal impairment. Abbreviations: pem, pemetrexed; pembro, pembrolizumab; plat, platinum.
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pemetrexed/pembrolizumab/platinum arm and 2 (1.5 %) patients in the
pemetrexed/placebo/platinum arm.

a slightly higher percentage of patients in the pemetrexed/pem
brolizumab/platinum arm compared to the control arm experienced
renal events, including acute kidney injury; however, grade ≥3 renal AE
incidence was consistently low, remaining below 2 %, in both treatment
arms across the study treatment period, by cycle. The incidence of
any-grade renal AEs was slightly higher in Cycles 5− 8 compared to
Cycles 1− 4, but it later stabilized and did not show a constantly
increasing pattern across all treatment cycles in either study arm. Of
note, this analysis examined the proportion of renal AEs at each treat
ment cycle and was not adjusted for differences in overall exposure.
Previous evidence suggests both immune checkpoint inhibitors and
chemotherapy may contribute to renal toxicity [20–22]. Thus, it is
recommended that patients who continue prolonged pembrolizumab/
pemetrexed therapy are monitored for renal function [17]. Under
standing and diagnosing the underlying mechanisms causing renal
toxicity may be useful in treating acute kidney injury among patients
treated with pembrolizumab/pemetrexed [20]. Although regimens that
do not involve maintenance chemotherapy in chemoimmunotherapy
regimens have been evaluated [23], there are no data to date showing a
direct comparison.
Pemetrexed and pembrolizumab each have a well-characterized
monotherapy safety profile for NSQ NSCLC treatment [9,24]. Hemato
logic toxicities such as anemia and neutropenia were the most common
grade 3–4 AEs among patients receiving pemetrexed/platinum in the
phase III PARAMOUNT study [9]. Non-hematologic toxicities such as
diarrhea, severe skin reaction, and pneumonitis were the most common
grade ≥3 AEs among patients receiving pembrolizumab monotherapy in
KEYNOTE-024 [24]. Any-grade immune-mediated AEs also occurred at
a higher rate among patients receiving pembrolizumab (29.2 %)
compared with patients receiving chemotherapy (4.7 %) [24]. For the
duration of this study, there were no differences observed in hemato
logic and non-hematologic AEs between treatment arms.
Immune-mediated AEs were slightly more common among patients
receiving pembrolizumab.
When interpreting the results presented in this post hoc exploratory
KEYNOTE-189 study, the following limitations should be considered.
The subgroup analyses of patients receiving ≥5 cycles of pemetrexed
excluded patients who discontinued due to progression or AEs occurring
within the first 4 cycles. Additionally, this study was analyzed with data
from the first interim analysis. Since then, additional safety analyses
were reported from the final data analysis [15]; however, there were no
substantial differences observed in grade ≥3 AEs from each data cutoff
(interim analysis: pemetrexed/pembrolizumab/platinum arm, 67.2 %;
pemetrexed/placebo/platinum arm, 65.8 % [14] vs final analysis:
pemetrexed/pembrolizumab/platinum arm, 72.1 %; pemetrex
ed/placebo/platinum arm, 66.8 % [15]). We additionally analyzed
median time-to-onset of the first grade ≥3 AE, regardless of incidence, in
the all-subjects-as-treated population from each data cutoff and found
no substantial differences (Supplemental Table 3).

3.3.4. Renal adverse events
The incidence of any-grade renal toxicity ranged from a minimum of
2.3 % in Cycles 1− 4 among patients in the pemetrexed/pem
brolizumab/platinum arm, to a maximum of 4.8 % in Cycles 5− 8
(Table 1). In the pemetrexed/placebo/platinum arm, no grade ≥3 renal
adverse events were reported; the incidence of any-grade renal events
ranged from a minimum of 0.7 % in Cycles 1− 4 to a maximum of 2.0 %
in Cycles ≥13 (Table 1). The most common any-grade renal events
among patients in the pemetrexed/pembrolizumab/platinum arm were
acute kidney injury and renal failure; the most common renal events
among patients in the pemetrexed/placebo/platinum arm were chronic
kidney disease and renal failure (Table 1). In the pemetrexed/pem
brolizumab/platinum arm, there were no grade ≥3 AEs in Cycles 1− 4,
n = 5 (1.6 %) in Cycles 5− 8, n = 1 (0.4 %) in Cycles 9− 12, and n = 1 (0.4
%) in Cycles ≥13 (Table 1). No grade ≥3 renal AEs occurred in the
pemetrexed/placebo/platinum arm in any study cycle.
4. Discussion
These results provide an in-depth characterization of patterns of AE
onset and resolution, and renal toxicity incidence, in patients from the
KEYNOTE-189 trial. This detailed safety profile is critical to optimize
toxicity management, given treatment-induced toxicities can have
detrimental consequences, such as high pemetrexed discontinuation
rates (which may negatively affect efficacy outcomes) and a decrease in
health-related quality of life. Data presented here may help set expec
tations for physicians regarding common toxicities and the average
duration of these toxicities.
Across both treatment arms in this study, most non-hematologic
grade ≥3 AEs with incidence ≥2 % occurred in the first 4 cycles and
resolved within 2 weeks from onset. The outliers of these onset and
resolution ranges were pneumonitis and acute kidney injury, which
were the most common AEs leading to pembrolizumab discontinuation
(3 % and 2 %, respectively). Although it is well known that those
immune-related AEs have late onset, pneumonitis in this study occurred
slightly later (approximately 18 weeks) compared to the previously re
ported median time-to-onset (8–10 weeks) of immune-related pneu
monitis after immunotherapy was initiated [18,19]. All hematologic AEs
with incidence ≥2 % in both treatment arms occurred in the first 4 cycles
and resolved within 2 weeks from onset. The percentage of patients who
discontinued pemetrexed or pembrolizumab due to an AE ranged from
1.5 % to 3 % during the first 4 cycles, and never surpassed 3 % in sub
sequent cycles. Over the course of the study, the incidence of grade ≥3
hematologic or non-hematologic AEs did not increase in either treat
ment arm.
Real-world data previously demonstrated that the majority of pa
tients with NSQ NSCLC who received the KEYNOTE-189 treatment
regimen did not receive combination pembrolizumab/pemetrexed
maintenance after the first 4 cycles [16], possibly due to perceived
safety concerns, including renal toxicity [17,20–22]. Renal toxicity,
which can occur during therapy with single-agent pembrolizumab [21]
or pemetrexed [22], appears to be more frequent in the combination
setting of pembrolizumab/pemetrexed compared with either agent
alone [17], and has been documented for immune checkpoint inhibitors
[20] and pemetrexed [22]. Renal function may become impaired
through several distinct mechanisms – either via the programmed cell
death protein-1 (PD-1)/PD-L1 pathway, or by tubular toxicity from
chemotherapeutic agents [17]. In one retrospective, hospital-based,
cohort study of 359 patients consecutively enrolled who had NSCLC
and were treated with pemetrexed, 21 % experienced clinically relevant
decline in renal function after pemetrexed treatment, and 8.1 % dis
continued pemetrexed due to nephrotoxicity; cumulative pemetrexed
dose was identified as a risk factor for nephrotoxicity [22]. In our study,

4.1. Conclusions
In KEYNOTE-189, most grade ≥3 AEs first occurred within 3 months
from administering the first study treatment and resolved within 2
weeks from onset. In addition, most discontinuations due to AEs
occurred during the first 4 cycles. These results suggest toxicity was not
accumulated in later treatment cycles, thus discontinuation of peme
trexed should be carefully considered due to the benefit of combination
with pembrolizumab. Overall renal AE incidence was low across both
treatment arms but slightly higher in the pembrolizumab combination.
Importantly, the incidence did not continue to increase across all
treatment cycles. In addition to the previous KEYNOTE-189 reports,
these results provide useful safety information and details on the timing
and management of the most commonly occurring AEs.
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